The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study of two doses of pixantrone in patients with metastatic breast cancerĀ (N1031, Alliance).
Kostandinos Sideras
No relevant relationships to disclose
Alvaro Moreno-Aspitia
No relevant relationships to disclose
Richard Charles Tenglin
No relevant relationships to disclose
Heshan Liu
No relevant relationships to disclose
Wilma L. Lingle
No relevant relationships to disclose
Monica Madden Reinholz
No relevant relationships to disclose
Kevin C Halling
No relevant relationships to disclose
Beiyun Chen
No relevant relationships to disclose
Gerald G. Gross
No relevant relationships to disclose
Rex Bradford Mowat
No relevant relationships to disclose
Shaker R. Dakhil
No relevant relationships to disclose
Edith A. Perez
No relevant relationships to disclose